research round-up |
research round-up
EFFICACY AND SAFETY OF A NEW HYALURONIC ACID DERMAL FILLER IN THE TREATMENT OF MODERATE NASOLABIAL FOLDS
Rzany B, Bayerl C, Bodokh I et al. J Cosmet Laser Ther 2011; 13(3): 107–12
correction of facial soft tissue defects. Objective: To compare the efficacy and safety of a novel Ha filler, emervel® classic, with those of restylane in the treatment of moderate nasolabial folds. Methods: This was a split-face, randomized and evaluator-blinded comparison study. subjects were randomized to receive an injection of emervel classic or restylane on their left or right side. efficacy was evaluated based on the change in Wrinkle severity rating score (Wsrs) from baseline. local tolerability was assessed based on subject diary, which recorded the severity of
H
yaluronic acid (Ha) fillers sucH as restylane® are frequently used for the
erythema, oedema/swelling, bruising, pain/ tenderness and pruritus during the first 3 weeks after injection. Results: The interim results 6 months after injection are reported. at week 24, the mean improvement in Wsrs from baseline was 0.83 ± 0.51 for emervel classic, similar to that for restylane (0.90 ± 0.57). a similar volume of both fillers was injected. Most local tolerability events were mild and transient. erythema, oedema/ swelling, and pain/tenderness were significantly less severe and disappeared faster with emervel classic than with restylane (at least p < 0.05). Conclusion: emervel classic provides similar efficacy and better overall local tolerability compared with restylane 6 months after treatment of moderate nasolabial folds.
PIOGLITAZONE: A VALUABLE COMPONENT OF COMBINATION THERAPY FOR TYPE 2 DIABETES MELLITUS
Papanas N, Katsiki N, Hatzitolios AI, Maltezos E. Expert Opin Pharmacother 2011; 12(10): 1457–61
60 ❚
mellitus (T2dM). Pioglitazone is now the only thiazolidinedione approved for the treatment of T2dM and can be administered in combination with metformin, sulfonylureas, exenatide, dipeptidyl peptidase 4 (dPP-4) inhibitors or insulin. it improves glycemic control with an extremely low incidence of hypoglycemia. in addition to reducing insulin resistance, it may also improve pancreatic beta-cell secretory function. Moreover, it exhibits a variety of favorable pleiotropic
s July 2011 |
prime-journal.com
everal classes of drugs Have been developed to treat type 2 diabetes
a round-up of the most recently published academic articles and research
effects. The latter include anti-inflammatory, antioxidant, vasoprotective, antihypertensive and hypolipidemic actions. finally, this agent has been shown to improve experimental diabetic neuropathy and alleviate neuropathic pain, as well as decreasing urinary albumin excretion in patients with diabetes. Thus, pioglitazone emerges as a valuable hypoglycemic agent for combination therapy in T2dM. importantly, however, patients should be appropriately selected, especially to avoid those with heart failure, in order to minimize adverse events attributable to water retention.
HISTOPATHOLOGICAL FOLLOW- UP BY TISSUE MICRO-ARRAY IN A SURVIVAL STUDY AFTER MELANOMA TREATED BY NANOSECOND PULSED ELECTRIC FIELDS (NSPEF)
Chen X, Chen X, Swanson RJ, Schoenback KH, Yin S, Zheng S. J Dermatolog Treat 2011; 22(3): 153–61
can affect the intracellular structures of melanoma within weeks. nsPef is a non-drug, non-thermal treatment using ultrashort, intense pulsed electric fields with nanosecond durations. in the current study we followed up melanoma histopathology and metastasis with tissue micro-array 5 months post-nsPef. after nsPef treatment, tumor growth, tumor histology, metastasis, peri-tumor vessel and micro-vessel density were examined for the effect of nsPef treatment on melanoma in vivo. The 17 nsPef-treated mice were tumor-free for 169 days, significantly longer
a
recenT sTudy Has sHoWn THaT nanosecond pulsed electric fields (nsPef)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84